NEO's Aroon Indicator triggered a bullish signal on September 30, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 189 similar instances where the Aroon Indicator showed a similar pattern. In 164 of the 189 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 87%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 59 cases where NEO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
Following a +3.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where NEO advanced for three days, in 215 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
NEO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The 10-day RSI Indicator for NEO moved out of overbought territory on September 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 23 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.
The Momentum Indicator moved below the 0 level on September 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NEO as a result. In 72 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for NEO turned negative on September 25, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 39 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
NEO moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NEO crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NEO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Tickeron Seasonality Score of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. NEO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.155) is normal, around the industry mean (72.578). P/E Ratio (49.505) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (0.060) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (3.189) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NEO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
STIM saw its Momentum Indicator move below the 0 level on September 21, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned negative. In 72 of the 80 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
STIM moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for STIM crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STIM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for STIM entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where STIM advanced for three days, in 228 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
STIM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.905) is normal, around the industry mean (10.930). P/E Ratio (0.000) is within average values for comparable stocks, (100.178). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (1.250) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. STIM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STIM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
NEO | STIM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 27 | 54 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 58 Fair valued | 42 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 92 | 99 | |
PRICE GROWTH RATING 1..100 | 36 | 63 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 34 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
STIM's Valuation (42) in the Medical Specialties industry is in the same range as NEO (58) in the Medical Or Nursing Services industry. This means that STIM’s stock grew similarly to NEO’s over the last 12 months.
STIM's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as NEO (100) in the Medical Or Nursing Services industry. This means that STIM’s stock grew similarly to NEO’s over the last 12 months.
NEO's SMR Rating (92) in the Medical Or Nursing Services industry is in the same range as STIM (99) in the Medical Specialties industry. This means that NEO’s stock grew similarly to STIM’s over the last 12 months.
NEO's Price Growth Rating (36) in the Medical Or Nursing Services industry is in the same range as STIM (63) in the Medical Specialties industry. This means that NEO’s stock grew similarly to STIM’s over the last 12 months.
NEO's P/E Growth Rating (100) in the Medical Or Nursing Services industry is in the same range as STIM (100) in the Medical Specialties industry. This means that NEO’s stock grew similarly to STIM’s over the last 12 months.
| NEO | STIM | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 72% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 75% | 1 day ago 89% |
| Momentum ODDS (%) | 1 day ago 85% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 83% | N/A |
| TrendWeek ODDS (%) | 1 day ago 78% | 1 day ago 87% |
| TrendMonth ODDS (%) | 1 day ago 85% | 1 day ago 88% |
| Advances ODDS (%) | 1 day ago 77% | 11 days ago 88% |
| Declines ODDS (%) | 10 days ago 80% | 3 days ago 89% |
| BollingerBands ODDS (%) | 1 day ago 72% | 1 day ago 81% |
| Aroon ODDS (%) | 1 day ago 87% | 1 day ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NEO’s FA Score shows that 0 FA rating(s) are green while STIM’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NEO’s TA Score shows that 4 TA indicator(s) are bullish while STIM’s TA Score has 4 bullish TA indicator(s).
NEO (@Medical Specialties) experienced а +7.68% price change this week, while STIM (@Medical/Nursing Services) price change was -8.88% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.21%. For the same industry, the average monthly price growth was +0.79%, and the average quarterly price growth was +37.83%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.72%. For the same industry, the average monthly price growth was -5.75%, and the average quarterly price growth was -13.54%.
NEO is expected to report earnings on Nov 10, 2026.
STIM is expected to report earnings on Nov 10, 2026.
Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (-2.72% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PLU | 3.43 | 0.17 | +5.21% |
| Defiance Daily Target 2x Long PL ETF (PLU) | |||
| DDM | 64.14 | 1.32 | +2.10% |
| ProShares Ultra Dow30 (DDM) | |||
| BULZ | 38.98 | 0.01 | +0.03% |
| MicroSectors Solactive FANG & Innovation 3X Leveraged ETN (BULZ) | |||
| SSXU | 34.71 | N/A | N/A |
| Strategy Shares Day Hagan Smart Sector International ETF (SSXU) | |||
| CRWL | 87.75 | -3.13 | -3.45% |
| GraniteShares 2x Long CRWD Daily ETF (CRWL) | |||